Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors

Cancer Research

Volumn 71, Issue 5, 2011, Pages 1924-1932

  Fujiwara, Kenichiro ^a   Yuwanita, Inez ^b   Hollern, Daniel P ^b   Andrechek, Eran R ^b  

^a DUKE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETICS; HUMAN; MOUSE; MUTANT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TRANSGENICS; TUMOR VOLUME;

ANIMALS; BREAST NEOPLASMS; E2F TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 79952221879     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2386     Document Type: Article

References (34)

1. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98:11462-7. (Pubitemid 32928751)
2. Bild AH, Yao G, Chang JT, Chang JT, Wang Q, Potti A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
3. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M, et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 2003;34:226-30. (Pubitemid 36666937)
4. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A 2009;106:16387-92.
5. Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR. Patterns of cell signaling pathway activation that characterize mammary development. Development 2008;135:2403-13.
6. Ponzo MG, Lesurf R, Petkiewicz S, O'Malleyd FP, Pinnaduwagef D, Andrulisg IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009;106:12903-8.
7. DeGregori J, Johnson DG. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006;6:739-48. (Pubitemid 44725567)
8. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993;365:349-52. (Pubitemid 23288977)
9. DeGregori J, Leone G, Ohtani K, Miron A, Nevins JR. E2F1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclindependent kinase activity. Genes & Dev 1995;9:2873-87.
10. Wu L, Timmers C, Maiti B, Saavedra HI, Ling Sang L, Chong GT, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001;414:457-62. (Pubitemid 34173728)
11. Timmers C, Sharma N, Opavsky R, Maiti B, Wu L, Wu J, et al. E2f1, E2f2, and E2f3 control target expression and cellular proliferation via a p53-dependent negative feedback loop. Mol Cell Biol 2007;27:65-78.
12. Kong L-J, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene 2007;26:321-7. (Pubitemid 46122822)
13. Kowalik TF, DeGregori J, Leone G, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation is modulated by mdm2. Cell Growth & Diff 1998;9:113-8. (Pubitemid 128472551)
14. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S regulatory genes. 1995;15:4215-24.
15. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995;69:2491-500.
16. Hallstrom TC, Nevins JR. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A 2003;100:10848-53. (Pubitemid 37140116)
17. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 2001;8:105-13. (Pubitemid 32772909)
18. Rempel RE, Mori S, Gasparetto M, Glozak MA, Andrechek ER, Adler SB, et al. A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet 2009;5:e1000640.
19. Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ, Johnson DG. E2F2 suppresses Myc-induced proliferation and tumorigenesis. Mol Carcinog 2009.
20. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawforda MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 2010;107:6994-9.
21. Barry WTBINREG. [Internet] 2010[cited 2010 12/7/2010]; Available from:http://www.duke.edu/~dinbarry/BINREG/
22. Desmedt C, Piette F, Loi S, Yixin Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007;13:3207-14. (Pubitemid 46944903)
23. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Johanna Smeds J, et al. Gene expression profiling in breast cancer:understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72. (Pubitemid 43264710)
24. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996;85:549-61. (Pubitemid 26157193)
25. Murga M, Fernandez-Capetillo O, Field SJ, Moreno B, R.-Borlado L, Fujiwara Y, et al. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity 2001;15:959-70. (Pubitemid 34075376)
26. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA. E2f3 is critical for normal cellular proliferation. Genes Dev 2000;14:690-703. (Pubitemid 30176823)
27. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627-37. (Pubitemid 15176093)
28. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, et al. Developmental stage determines the effects of MYC in the mammary epithelium. Development 2005;132:1147-60. (Pubitemid 40484947)
29. Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data biases. Bioinformatics 2004;20:105-14. (Pubitemid 38094234)
30. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
31. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23. (Pubitemid 36842560)
32. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007;8:R76.
33. Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. Cancer Res 2002;62:3276-81. (Pubitemid 34602425)
34. Jamerson MH, Johnson MD, Furth PA, Dickson RB. Early parity significantly elevates mammary tumor incidence in MMTV-c-myc transgenic mice. Transgenic Res 2003;12:747-50. (Pubitemid 38024835)